EndometriosisNCT07481617
Laparoscopic Sclerotherapy for the Management of Ovarian Endometriomas
An observational study of Endometriosis and Endometrioma, run by Northwestern University.
Trial summary
The objective of this study is to evaluate the effect of laparoscopic sclerotherapy on ovarian reserve and its overall efficacy in the treatment of endometriomas. Ovarian reserve will be assessed using preoperative and postoperative anti-Müllerian hormone (AMH) levels and antral follicle count (AFC). Read more about this study
- Who is it for?
- Ages 18 to 55 years, women only
- Conditions the study is for
- Endometriosis, Endometrioma, Sclerotherapy
- What is being tested?
- Laparoscopic sclerotherapy
- Type of treatment
- Surgery or procedure
- How many people
- 20 participants
- Where
- No sites listed yet
- Study dates
- 16 Oct 2026to 30 Dec 2027
- How long will I take part?
- 6 Weeks
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- Women only
- No healthy volunteers
- Adult
Study population: Patients with at least one endometrioma > 4 cm, interested in ovarian conservation and surgical management of the endometrioma.
Who may be able to join
- English speaking
- Age of 18 or greater
- At least one ovarian endometrioma > 4 cm in size
- Desires to proceed with surgical management of the endometrioma
Who cannot join
- Known diminished ovarian reserve (AMH < 1.0)
- Known allergies to ethanol solutions
- Pregnancy
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Juan Avitia, MPH contact
About this study
Official title: Laparoscopic Sclerotherapy for Management of Endometriomas: A Pilot Study Evaluating Impact on Ovarian Reserve
The objective of this study is to evaluate the effect of laparoscopic sclerotherapy on ovarian reserve and its overall efficacy in the treatment of endometriomas. Ovarian reserve will be assessed using preoperative and postoperative anti-Müllerian hormone (AMH) levels and antral follicle count (AFC). Traditionally, ovarian endometriomas are managed by complete cystectomy; however, multiple studies including a large systematic review and meta-analysis-have demonstrated that cystectomy significantly reduces ovarian reserve, with an average decline in AMH of 1.77 ng/mL within one to six weeks postoperatively without recovery to baseline after many months. Sclerotherapy has historically been a potential alternative, typically performed by interventional radiology via transvaginal, transabdominal, or transgluteal drainage. This percutaneous approach, however, precludes direct visualization of the cyst and surgical management of concurrent conditions including endometriosis peritoneal disease, excision, adhesions, or tubal disease.
Several studies have explored the feasibility and effectiveness of laparoscopic sclerotherapy, reporting encouraging results regarding its safety, increased AFC compared with cystectomy, and comparable pregnancy rates. Nonetheless, none of these studies have been conducted in the United States, and few have utilized a laparoscopic approach. Further research is therefore warranted to establish the accessibility and reproducibility of this technique. The investigators aim to conduct the first U.S.-based study evaluating the impact of laparoscopic sclerotherapy on ovarian reserve. The primary outcome will be the change in AMH and AFC at six weeks postoperatively. Consistent with prior evidence, the investigators hypothesize that laparoscopic sclerotherapy will result in a smaller decline in ovarian reserve compared with traditional cystectomy.
Read the detailed description
Primary Endpoint:
- The change in pre op and post op AMH levels and Antral Follicle Count in patients with ovarian endometriomas.
Secondary Endpoints:
- Evidence of cyst resolution at 6-week ultrasound
- Recurrence of new endometriomas
- If any further surgical interventions are performed at the same time as sclerotherapy such as excision of endometriosis, tubal evaluation, hysteroscopy, etc.
Exploratory endpoints:
- Need for acute post op unplanned visits due to pain or concerns for infection
- Incidence of ER visits
STUDY INTERVENTION(S) / INVESTIGATIONAL AGENT(S):
This study involves the use of nearly 100% ethanol., also called ABLYSINOL, or an additional Brand name, currently in stock at the Northwestern Pharmacy- Avenacy Dehydrated alcohol ( ≥ 99% ethanol solution). Ethanol is available over the counter in 96% formulations. The Northwestern pharmacy does have 100% ethanol available for other surgical specialties that use the same agent for other sclerotherapy procedures. (Avenacy Dehydrated Alcohol, ≥ 99% ethanol solution).
IND Exemption using criteria: Category #1. Ethanol is lawfully marked in the U.S. The research is not intended to be reported to the FDA as a well-controlled study in support of a new indication for use nor intended to be used to support any other significant change in labeling for the drug. The research is not intended to support significant changes in advertising the product. The research does not involve a route, quantity, or patient population that significantly increases risk associated with the use of the drug product.
PROCEDURES INVOLVED:
Participants in this study will be screened through patients that present to the Center for Complex Gynecology at Northwestern Medicine. During their initial consultation for surgical management if they elect to proceed with surgical management of their endometriomas, the option for laparoscopic sclerotherapy and participation in this study will be offered if they meet all inclusion criteria. If the patient is not interested in participating in the study, they can still undergo surgical management with a cystectomy.
If patients express interest in participating in the study on laparoscopic sclerotherapy, a member of the study team will provide detailed information about the study during their clinic visit. Written informed consent will be obtained at that time, allowing participants adequate opportunity to ask questions and consider their decision.
In cases where the participant is unable to complete the consent process during the clinic visit, they will be provided with the consent form in advance and given time to review it. If the preoperative visit occurs via telehealth and the patient expressed interest in the study, the participant will be emailed a copy of the consent form and recruitment document. One of the members of the study team will also call the patient prior to the day of surgery to ensure all of their questions are answered; the consent form will then be signed on the day of surgery. As all patients are required to arrive 2 hours prior to their surgical time, there is plenty of time allotted to ensure a thorough review and discussion of the consent form and surgical plan is completed with the research team prior to surgery. Written consent will then be obtained on the day of surgery, prior to any study-related procedures, ensuring that participants have had sufficient time to consider their participation and have all questions addressed.
PRE OP PROTOCOL:
Patients will obtain pre-op AMH and an ultrasound guided AFC as it is the standard of care.
If a patient consents to the study, their AMH, AFC, size and laterality of the ovarian cyst will be documented.
Other information obtained from the chart will include age, parity, history of prior ovarian cystectomy, reproductive history including if patient is currently undergoing fertility treatment, history of prior endometriosis surgery, MRI evidence of deep infiltrating endometriosis.
SURGICAL PROTOCOL:
- Enter the abdomen laparoscopically as per routine.
- Perform a survey of the abdomen and pelvis as as per routine.
- Evaluate the ovarian cyst as per routine.
- Place lap pads in the abdomen and cover the bowel underlying the cyst that the participant will be working on to help protect it from incidental spillage.
- Make a small incision within the capsule of the cyst to be able to fit suction and drain the cyst, as indicated for any other case.
- Irrigate the inner wall of the cyst with saline, as is standing of care for cyst drainage.
- Place a 16 fr silicone foley catheter through the trocar to the cyst (or smaller silicone catheter if indicated by the size of the cyst. Guide the cyst wall over the foley tip and fill the balloon so that the catheter stays in place within the cyst wall.
- Fill the cyst with the Avenacy Dehydrated Alcohol (≥ 99% ethanol solution)ethanol solution, approximately 60% of the estimated volume of the cyst. Based on size estimates to calculate Volume, the investigators anticipate using approximately 40 mL for a 5 cm cyst with the amount needed varying based on the size of the ovarian cyst up to 100 mL. As the cyst is aspirated prior to the sclerotherapy this will also serve as a mechanism to know the volume capacity of the cyst. For example if 100 mL of endometriotic fluid is aspirated from the cyst, 60 mL of Avenacy Dehydrated Alcohol (≥ 99% ethanol solution) would then be used to fill the cyst of sclerotherapy.
- Leave the solution in place for 15 minutes (dwell time).
- The remainder of the endometriosis excision or evaluation of the pelvis can be performed at this time.
- After 15 minutes has elapsed aspirate the contents of the cyst.
- Evaluate the nonexposed walls of the cyst, resect any areas that did not receive any of the sclerosing agent.
- Continue remainder of the laparoscopy as indicated by the patient's clinical factors.
POST OP PROTOCOL:
Patients may be discharged from same day surgery as that is the standard of care. They will follow up for a 2-week and 6-week post-op visit as that is the standard of care. At the 6-week post op visit an AMH will be drawn, and an ultrasound Antral follicle count will be obtained. The blood draw will be completed in the lab by phlebotomy within the Lavin Pavillion. Approximately 5 mL will be drawn to obtain an AMH level. Any prior ER visits or sooner follow-ups due to patient concerns will be documented.
INCLUSION AND EXCLUSION CRITERIA
Inclusion criteria:
- English speaking
- Age of 18 or greater
- At least one ovarian endometrioma > 4 cm in size
- Desires to proceed with surgical management of the endometrioma
Exclusion Criteria:
- Known diminished ovarian reserve (AMH < 1.0)
- Known allergies to ethanol solutions
- Pregnancy
- Conditions
- Endometriosis, Endometrioma, Sclerotherapy, Laparoscopy
- Being tested
- Laparoscopic sclerotherapy
- Keywords
- laparoscopic sclerotherapy
- Medical subject headings
- Endometriosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Laparoscopic sclerotherapyProcedure or surgery
Standard of care for an endometrioma is a laparoscopic cystectomy. This procedure still uses laparoscopy however instead of a cystectomy, the ovarian cyst is drained and ethanol is instilled for sclerotherapy and then removed from the cyst. The benefit is hopefully a lesser impact on ovarian reserve as opposed to ovarian cystectomy.
| Study group | Role | What they receive |
|---|---|---|
| Laparoscopic Sclerotherapy | Patients who choose to undergo laparoscopic sclerotherapy for management of their ovarian endometrioma. Receives: Procedure: Laparoscopic sclerotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
AMH
Change in AMH from pre op appintment to 6 week post op appointment.
Measured: 6 weeks
Antral Follicle Count
An Ultrasound will be performed at 6 weeks post op to assess antral follicle count
Measured: 6 weeks
Secondary outcomes (3)
Endometrioma resolution
determine if endometrioma has resolved
Measured: 6 weeks
Endometrioma recurrence
Recurrence of ovarian endometrioma
Measured: 6 weeks
Post operative complications
Evaluate for any post op complications including, ER presentations and hospital admissions
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2026
- Study start16 Oct 2026 (estimated)
- Primary completion30 Nov 2027 (estimated)
- Study completion30 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for EndometriosisStudies of the same condition, open and under way.
- More trials run by Northwestern UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
- Target duration
- 6 Weeks
Sponsor and investigators
- Lead sponsor
- Northwestern University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Magdy Milad, MD, Northwestern University
- Investigators
- Magdy Milad, MD, Principal investigator, Northwestern University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07481617
- Sponsor's protocol ID
- STU00225154
- Status last verified
- Apr 2026
- First submitted
- 13 Mar 2026
- Last updated
- 24 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Garcia-Tejedor A, Guevara-Peralta R, Martinez-Garcia JM, Corbalan S, Aguero M, Gomez-Romero M, Cararach M, Castellarnau M, Rodriguez M, Lou-Mercade AC, Costa L, Rodriguez MJ, Huguet E, Carreras M, Castel-Segui AB, Font-Roig M, Royo S, Sarasa N, Candas B, Perez-Carton S, Ortega C, Pla MJ, Ponce J. Ultrasound-guided ethanol sclerotherapy versus laparoscopic surgery for endometriomas: a randomized clinical trial in a real-world setting. Arch Gynecol Obstet. 2025 Dec;312(6):2199-2210. doi: 10.1007/s00404-025-08205-1. Epub 2025 Nov 4.
PubMed 41186685Crestani A, Merlot B, Goualard PH, Huet C, Husson Z, Dennis T, Chanavaz-Lacheray I, Roman H. Laparoscopic sclerotherapy for ovarian endometriomas during surgery for deep endometriosis: Outcomes of a 134-patient cohort. Int J Gynaecol Obstet. 2025 Oct;171(1):431-437. doi: 10.1002/ijgo.70201. Epub 2025 May 7.
PubMed 40332134Crestani A, Merlot B, Dennis T, Chanavaz-Lacheray I, Roman H. Impact of Laparoscopic Sclerotherapy for Ovarian Endometriomas on Ovarian Reserve. J Minim Invasive Gynecol. 2023 Jan;30(1):32-38. doi: 10.1016/j.jmig.2022.10.001. Epub 2022 Oct 10.
PubMed 36228863Veth VB, Keukens A, Reijs A, Bongers MY, Mijatovic V, Coppus SFPJ, Maas JWM. Recurrence after surgery for endometrioma: a systematic review and meta-analyses. Fertil Steril. 2024 Dec;122(6):1079-1093. doi: 10.1016/j.fertnstert.2024.07.033. Epub 2024 Aug 5.
PubMed 39098538Lavadia CMM, Jeong HG, Ryu KJ, Park H. Ovarian reserve and IVF outcomes after ethanol ovarian sclerotherapy in women with endometrioma: a systematic review and meta-analysis. Reprod Biomed Online. 2025 Jul;51(1):104840. doi: 10.1016/j.rbmo.2025.104840. Epub 2025 Feb 16.
PubMed 40440796Martinez-Garcia JM, Candas B, Suarez-Salvador E, Gomez M, Merino E, Castellarnau M, Carreras M, Carrarach M, Subirats N, Gonzalez S, Fernandez-Montoli E, Ponce J, Garcia-Tejedor A. Comparing the effects of alcohol sclerotherapy with those of surgery on anti-Mullerian hormone and ovarian reserve after endometrioma treatment. A prospective multicenter pilot cohort study. Eur J Obstet Gynecol Reprod Biol. 2021 Apr;259:60-66. doi: 10.1016/j.ejogrb.2021.01.027. Epub 2021 Jan 22.
PubMed 33592391Fisch JD, Sher G. Sclerotherapy with 5% tetracycline is a simple alternative to potentially complex surgical treatment of ovarian endometriomas before in vitro fertilization. Fertil Steril. 2004 Aug;82(2):437-41. doi: 10.1016/j.fertnstert.2004.01.031.
PubMed 15302295Younis JS, Shapso N, Ben-Sira Y, Nelson SM, Izhaki I. Endometrioma surgery-a systematic review and meta-analysis of the effect on antral follicle count and anti-Mullerian hormone. Am J Obstet Gynecol. 2022 Jan;226(1):33-51.e7. doi: 10.1016/j.ajog.2021.06.102. Epub 2021 Jul 13.
PubMed 34265271Alborzi S, Zahiri Sorouri Z, Askari E, Poordast T, Chamanara K. The success of various endometrioma treatments in infertility: A systematic review and meta-analysis of prospective studies. Reprod Med Biol. 2019 Jun 19;18(4):312-322. doi: 10.1002/rmb2.12286. eCollection 2019 Oct.
PubMed 31607791Cohen A, Almog B, Tulandi T. Sclerotherapy in the management of ovarian endometrioma: systematic review and meta-analysis. Fertil Steril. 2017 Jul;108(1):117-124.e5. doi: 10.1016/j.fertnstert.2017.05.015. Epub 2017 Jun 1.
PubMed 28579409
Study at a glance
From the registry record, last updated by the sponsor on 24 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Laparoscopic Sclerotherapy for Management of Endometriomas: A Pilot Study Evaluating Impact on Ovarian Reserve
- ClinicalTrials.gov ID
- NCT07481617
- Acronym / sponsor ID
- STU00225154
- Conditions
- Endometriosis, Endometrioma, Sclerotherapy, Laparoscopy
- Keywords
- laparoscopic sclerotherapy
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Northwestern UniversityUniversity, hospital or other
- Study start
- 16 Oct 2026 (estimated)
- Primary completion
- 30 Nov 2027 (estimated)
- Study completion
- 30 Dec 2027 (estimated)
- First posted
- 19 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to evaluate the effect of laparoscopic sclerotherapy on ovarian reserve and its overall efficacy in the treatment of endometriomas. Ovarian reserve will be assessed using preoperative and postoperative anti-Müllerian hormone (AMH) levels and antral follicle count (AFC). Traditionally, ovarian endometriomas are managed by complete cystectomy; however, multiple studies including a large systematic review and meta-analysis-have demonstrated that cystectomy significantly reduces ovarian reserve, with an average decline in AMH of 1.77 ng/mL within one to six weeks postoperatively without recovery to baseline after many months. Sclerotherapy has historically been a potential alternative, typically performed by interventional radiology via transvaginal, transabdominal, or transgluteal drainage. This percutaneous approach, however, precludes direct visualization of the cyst and surgical management of concurrent conditions including endometriosis peritoneal disease, excision, adhesions, or tubal disease.
Several studies have explored the feasibility and effectiveness of laparoscopic sclerotherapy, reporting encouraging results regarding its safety, increased AFC compared with cystectomy, and comparable pregnancy rates. Nonetheless, none of these studies have been conducted in the United States, and few have utilized a laparoscopic approach. Further research is therefore warranted to establish the accessibility and reproducibility of this technique. The investigators aim to conduct the first U.S.-based study evaluating the impact of laparoscopic sclerotherapy on ovarian reserve. The primary outcome will be the change in AMH and AFC at six weeks postoperatively. Consistent with prior evidence, the investigators hypothesize that laparoscopic sclerotherapy will result in a smaller decline in ovarian reserve compared with traditional cystectomy.
Detailed description
Primary Endpoint:
- The change in pre op and post op AMH levels and Antral Follicle Count in patients with ovarian endometriomas.
Secondary Endpoints:
- Evidence of cyst resolution at 6-week ultrasound
- Recurrence of new endometriomas
- If any further surgical interventions are performed at the same time as sclerotherapy such as excision of endometriosis, tubal evaluation, hysteroscopy, etc.
Exploratory endpoints:
- Need for acute post op unplanned visits due to pain or concerns for infection
- Incidence of ER visits
STUDY INTERVENTION(S) / INVESTIGATIONAL AGENT(S):
This study involves the use of nearly 100% ethanol., also called ABLYSINOL, or an additional Brand name, currently in stock at the Northwestern Pharmacy- Avenacy Dehydrated alcohol ( ≥ 99% ethanol solution). Ethanol is available over the counter in 96% formulations. The Northwestern pharmacy does have 100% ethanol available for other surgical specialties that use the same agent for other sclerotherapy procedures. (Avenacy Dehydrated Alcohol, ≥ 99% ethanol solution).
IND Exemption using criteria: Category #1. Ethanol is lawfully marked in the U.S. The research is not intended to be reported to the FDA as a well-controlled study in support of a new indication for use nor intended to be used to support any other significant change in labeling for the drug. The research is not intended to support significant changes in advertising the product. The research does not involve a route, quantity, or patient population that significantly increases risk associated with the use of the drug product.
PROCEDURES INVOLVED:
Participants in this study will be screened through patients that present to the Center for Complex Gynecology at Northwestern Medicine. During their initial consultation for surgical management if they elect to proceed with surgical management of their endometriomas, the option for laparoscopic sclerotherapy and participation in this study will be offered if they meet all inclusion criteria. If the patient is not interested in participating in the study, they can still undergo surgical management with a cystectomy.
If patients express interest in participating in the study on laparoscopic sclerotherapy, a member of the study team will provide detailed information about the study during their clinic visit. Written informed consent will be obtained at that time, allowing participants adequate opportunity to ask questions and consider their decision.
In cases where the participant is unable to complete the consent process during the clinic visit, they will be provided with the consent form in advance and given time to review it. If the preoperative visit occurs via telehealth and the patient expressed interest in the study, the participant will be emailed a copy of the consent form and recruitment document. One of the members of the study team will also call the patient prior to the day of surgery to ensure all of their questions are answered; the consent form will then be signed on the day of surgery. As all patients are required to arrive 2 hours prior to their surgical time, there is plenty of time allotted to ensure a thorough review and discussion of the consent form and surgical plan is completed with the research team prior to surgery. Written consent will then be obtained on the day of surgery, prior to any study-related procedures, ensuring that participants have had sufficient time to consider their participation and have all questions addressed.
PRE OP PROTOCOL:
Patients will obtain pre-op AMH and an ultrasound guided AFC as it is the standard of care.
If a patient consents to the study, their AMH, AFC, size and laterality of the ovarian cyst will be documented.
Other information obtained from the chart will include age, parity, history of prior ovarian cystectomy, reproductive history including if patient is currently undergoing fertility treatment, history of prior endometriosis surgery, MRI evidence of deep infiltrating endometriosis.
SURGICAL PROTOCOL:
- Enter the abdomen laparoscopically as per routine.
- Perform a survey of the abdomen and pelvis as as per routine.
- Evaluate the ovarian cyst as per routine.
- Place lap pads in the abdomen and cover the bowel underlying the cyst that the participant will be working on to help protect it from incidental spillage.
- Make a small incision within the capsule of the cyst to be able to fit suction and drain the cyst, as indicated for any other case.
- Irrigate the inner wall of the cyst with saline, as is standing of care for cyst drainage.
- Place a 16 fr silicone foley catheter through the trocar to the cyst (or smaller silicone catheter if indicated by the size of the cyst. Guide the cyst wall over the foley tip and fill the balloon so that the catheter stays in place within the cyst wall.
- Fill the cyst with the Avenacy Dehydrated Alcohol (≥ 99% ethanol solution)ethanol solution, approximately 60% of the estimated volume of the cyst. Based on size estimates to calculate Volume, the investigators anticipate using approximately 40 mL for a 5 cm cyst with the amount needed varying based on the size of the ovarian cyst up to 100 mL. As the cyst is aspirated prior to the sclerotherapy this will also serve as a mechanism to know the volume capacity of the cyst. For example if 100 mL of endometriotic fluid is aspirated from the cyst, 60 mL of Avenacy Dehydrated Alcohol (≥ 99% ethanol solution) would then be used to fill the cyst of sclerotherapy.
- Leave the solution in place for 15 minutes (dwell time).
- The remainder of the endometriosis excision or evaluation of the pelvis can be performed at this time.
- After 15 minutes has elapsed aspirate the contents of the cyst.
- Evaluate the nonexposed walls of the cyst, resect any areas that did not receive any of the sclerosing agent.
- Continue remainder of the laparoscopy as indicated by the patient's clinical factors.
POST OP PROTOCOL:
Patients may be discharged from same day surgery as that is the standard of care. They will follow up for a 2-week and 6-week post-op visit as that is the standard of care. At the 6-week post op visit an AMH will be drawn, and an ultrasound Antral follicle count will be obtained. The blood draw will be completed in the lab by phlebotomy within the Lavin Pavillion. Approximately 5 mL will be drawn to obtain an AMH level. Any prior ER visits or sooner follow-ups due to patient concerns will be documented.
INCLUSION AND EXCLUSION CRITERIA
Inclusion criteria:
- English speaking
- Age of 18 or greater
- At least one ovarian endometrioma > 4 cm in size
- Desires to proceed with surgical management of the endometrioma
Exclusion Criteria:
- Known diminished ovarian reserve (AMH < 1.0)
- Known allergies to ethanol solutions
- Pregnancy
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 6 Weeks
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Laparoscopic Sclerotherapy | – | Procedure: Laparoscopic sclerotherapyPatients who choose to undergo laparoscopic sclerotherapy for management of their ovarian endometrioma. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Patients with at least one endometrioma > 4 cm, interested in ovarian conservation and surgical management of the endometrioma.
Key inclusion criteria (4 listed)
- English speaking
- Age of 18 or greater
- At least one ovarian endometrioma > 4 cm in size
- Desires to proceed with surgical management of the endometrioma
Key exclusion criteria (3 listed)
- Known diminished ovarian reserve (AMH < 1.0)
- Known allergies to ethanol solutions
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Laparoscopic sclerotherapyStandard of care for an endometrioma is a laparoscopic cystectomy. This procedure still uses laparoscopy however instead of a cystectomy, the ovarian cyst is drained and ethanol is instilled for sclerotherapy and then removed from the cyst. The benefit is hopefully a lesser impact on ovarian reserve as opposed to ovarian cystectomy. | Procedure or surgery | Laparoscopic Sclerotherapy |
Primary outcome
AMH
Time frame: 6 weeks
Change in AMH from pre op appintment to 6 week post op appointment.
Antral Follicle Count
Time frame: 6 weeks
An Ultrasound will be performed at 6 weeks post op to assess antral follicle count
3 secondary outcomes
Endometrioma resolution
Time frame: 6 weeks
Endometrioma recurrence
Time frame: 6 weeks
Post operative complications
Time frame: 6 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Aug 2026.
- Background: PubMed 41186685Garcia-Tejedor A, Guevara-Peralta R, Martinez-Garcia JM, Corbalan S, Aguero M, Gomez-Romero M, Cararach M, Castellarnau M, Rodriguez M, Lou-Mercade AC, Costa L, Rodriguez MJ, Huguet E, Carreras M, Castel-Segui AB, Font-Roig M, Royo S, Sarasa N, Candas B, Perez-Carton S, Ortega C, Pla MJ, Ponce J. Ultrasound-guided ethanol sclerotherapy versus laparoscopic surgery for endometriomas: a randomized clinical trial in a real-world setting. Arch Gynecol Obstet. 2025 Dec;312(6):2199-2210. doi: 10.1007/s00404-025-08205-1. Epub 2025 Nov 4.
- Background: PubMed 40332134Crestani A, Merlot B, Goualard PH, Huet C, Husson Z, Dennis T, Chanavaz-Lacheray I, Roman H. Laparoscopic sclerotherapy for ovarian endometriomas during surgery for deep endometriosis: Outcomes of a 134-patient cohort. Int J Gynaecol Obstet. 2025 Oct;171(1):431-437. doi: 10.1002/ijgo.70201. Epub 2025 May 7.
- Background: PubMed 36228863Crestani A, Merlot B, Dennis T, Chanavaz-Lacheray I, Roman H. Impact of Laparoscopic Sclerotherapy for Ovarian Endometriomas on Ovarian Reserve. J Minim Invasive Gynecol. 2023 Jan;30(1):32-38. doi: 10.1016/j.jmig.2022.10.001. Epub 2022 Oct 10.
- Background: PubMed 39098538Veth VB, Keukens A, Reijs A, Bongers MY, Mijatovic V, Coppus SFPJ, Maas JWM. Recurrence after surgery for endometrioma: a systematic review and meta-analyses. Fertil Steril. 2024 Dec;122(6):1079-1093. doi: 10.1016/j.fertnstert.2024.07.033. Epub 2024 Aug 5.
- Background: PubMed 40440796Lavadia CMM, Jeong HG, Ryu KJ, Park H. Ovarian reserve and IVF outcomes after ethanol ovarian sclerotherapy in women with endometrioma: a systematic review and meta-analysis. Reprod Biomed Online. 2025 Jul;51(1):104840. doi: 10.1016/j.rbmo.2025.104840. Epub 2025 Feb 16.
- Background: PubMed 33592391Martinez-Garcia JM, Candas B, Suarez-Salvador E, Gomez M, Merino E, Castellarnau M, Carreras M, Carrarach M, Subirats N, Gonzalez S, Fernandez-Montoli E, Ponce J, Garcia-Tejedor A. Comparing the effects of alcohol sclerotherapy with those of surgery on anti-Mullerian hormone and ovarian reserve after endometrioma treatment. A prospective multicenter pilot cohort study. Eur J Obstet Gynecol Reprod Biol. 2021 Apr;259:60-66. doi: 10.1016/j.ejogrb.2021.01.027. Epub 2021 Jan 22.
- Background: PubMed 15302295Fisch JD, Sher G. Sclerotherapy with 5% tetracycline is a simple alternative to potentially complex surgical treatment of ovarian endometriomas before in vitro fertilization. Fertil Steril. 2004 Aug;82(2):437-41. doi: 10.1016/j.fertnstert.2004.01.031.
- Background: PubMed 34265271Younis JS, Shapso N, Ben-Sira Y, Nelson SM, Izhaki I. Endometrioma surgery-a systematic review and meta-analysis of the effect on antral follicle count and anti-Mullerian hormone. Am J Obstet Gynecol. 2022 Jan;226(1):33-51.e7. doi: 10.1016/j.ajog.2021.06.102. Epub 2021 Jul 13.
- Background: PubMed 31607791Alborzi S, Zahiri Sorouri Z, Askari E, Poordast T, Chamanara K. The success of various endometrioma treatments in infertility: A systematic review and meta-analysis of prospective studies. Reprod Med Biol. 2019 Jun 19;18(4):312-322. doi: 10.1002/rmb2.12286. eCollection 2019 Oct.
- Background: PubMed 28579409Cohen A, Almog B, Tulandi T. Sclerotherapy in the management of ovarian endometrioma: systematic review and meta-analysis. Fertil Steril. 2017 Jul;108(1):117-124.e5. doi: 10.1016/j.fertnstert.2017.05.015. Epub 2017 Jun 1.
- Individual participant dataSharing planned: No
Related trials for Endometriosis
Not yet recruiting
Prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in Women With Endometriosis
SIBO, Endometriosis
Recruiting
Endometriosis Transcriptomic Cell Atlas
Endometriosis, Infertility
Not yet recruiting
Psychotherapy in Patients With Endometriosis: Cognitive Behavioral Therapy Versus Acceptance and Commitment Therapy
Endometriosis, Adenomyosis
Not yet recruitingObservational study
Impact of a Diagnosis or Lack of a Diagnosis of Endometriosis Via a Saliva Test on Pain Catastrophizing, Quality of Life, Symptoms of Anxiety and Depression, and Treatment Adherence
Endometriosis
RecruitingPhase 4
Estetrol/Drospirenone to Reduce the Average Size of Endometriomas
Ovarian Endometrioma, Endometrioma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Juan Avitia, MPH contact
Magdy Milad, MD principal investigator
Northwestern University
Questions about this trial
What is this clinical trial studying?
An observational study of Endometriosis and Endometrioma, run by Northwestern University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 24 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hannah Pope, MD (3126946773, hannah.pope@nm.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AMH (time frame: 6 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07481617, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2026.